Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-508-2_4

Chapter 10: Future Directions and Translational Potential: From Bench to Bedside

Jyoti Jwala[1], Sonal Sharma[2], Himanshi[3], Basharat Nawaz[4], Sudipa Debnath[5], Radia Khushi[6], Kajal Sharma[7], Binita Ghosh[8]*

[1]*Clinical Pharmacist, Yashoda Super speciality hospital, Kaushambi, 201010, Ghaziabad, India.*
[2]*Department of Quality Assurance, Mahatma Gandhi College of pharmaceutical Sciences, Tonk Road, Jaipur, Rajasthan, India.*
[3]*Department of Pharmacy Practice, RAMA University, Mandhana, Kanpur, 209217, India.*
[4]*Department of Pharmacy Practice, Mewar University, Gangrar, Chittorgarh, Rajasthan, 312901, India.*
[5]*Clinical Research Coordinator, Department of Neurology Research, Fortis Hospital, Sector 5, Malviya Nagar, Jaipur, 302017, Rajasthan, India.*
[6]*Department of Pharmaceutical Sciences, Saurashtra University, Rajkot, 360005, India.*
[7]*Sant Hirdaram Medical College of Naturopathy and Yogic Sciences for Women Bhopal (MP), India.*
[8]*Department of Pharmacy Practice, Mahatma Gandhi College of pharmaceutical Sciences, Tonk Road, Jaipur, Rajasthan, India.*

Corresponding Author
Dr. Binita Ghosh
Email: ***binitaghosh66746@gmail.com***

Abstract

Background: Parkinson's disease (PD) is a chronic neurodegenerative disorder marked by motor dysfunction and dopaminergic neuronal loss. Traditional herbal remedies, particularly *Ginkgo biloba* and *Gastrodia elata*, have shown neuroprotective and anti-inflammatory effects in preclinical studies. However, clinical application has been limited by poor bioavailability (BA) and lack of targeted delivery systems. With the evolution of nanotechnology and advanced drug delivery platforms, the integration of ancient herbal knowledge with modern nanoscience presents a promising avenue for effective PD therapy.

Objective: This chapter aims to explore the future prospects and translational potential of nano-based targeted delivery systems for *Ginkgo and Gastrodia* in the treatment of PD, highlighting the shift from preclinical evidence to clinical applicability.

Methodology: A comprehensive review of existing literature was conducted, encompassing *in vitro* and *in vivo* studies on the pharmacological effects of *Ginkgo and Gastrodia*, followed by an analysis of current nanocarrier systems (liposomes, NPss, nanoemulsions) utilized in CNS drug delivery. Case studies and emerging clinical trials were evaluated to understand the translational pipeline from laboratory research to human application.

Results: Findings reveal that NPs-mediated delivery significantly enhances the BA, blood-brain barrier (BBB) penetration, and sustained release of *Ginkgo and Gastrodia* bioactives. Several nanoformulations demonstrated neuroprotective effects, reduction in oxidative stress, and improvement in motor function in PD animal models. Initial clinical trials reflect promising safety profiles and improved therapeutic efficacy compared to conventional preparations.

Conclusion: The integration of ancient herbal therapeutics with modern nanotechnology marks a transformative step toward personalized and efficient PD treatment. The translational shift from bench to bedside, while still facing regulatory and scalability challenges, is increasingly feasible. Continued interdisciplinary research and collaborative efforts are crucial for advancing these nano-herbal formulations into clinical use for PD.

Keywords: *Nanoscience, nanocarriers, traditional Chinese medicine, bioavailability, personalized.*

1. Introduction

Parkinson's disease (PD) represents a multifactorial neurodegenerative disorder marked by a progressive decline in motor control, primarily due to the selective degeneration of dopaminergic neurons in the substantia nigra. This degeneration disrupts nigrostriatal pathways, impairing dopamine synthesis, which is essential for modulating movement, coordination, and a range of cognitive and emotional functions [1-2]. Beyond classical motor features, non-motor symptoms such as depression, olfactory dysfunction, gastrointestinal disturbances, and sleep disorders frequently emerge early in the disease course, indicating that PD affects widespread neural systems [3].

The etiology of PD is complex and involves the interplay of genetic predispositions, environmental toxins, oxidative damage, mitochondrial impairment, and aberrant protein aggregation-particularly the accumulation of α-synuclein into Lewy bodies, which is pathognomonic of the disease [4-5]. As PD advances, neuronal loss becomes widespread and irreversible, emphasizing the importance of early, targeted intervention that extends beyond dopamine replacement alone [6]. Traditional pharmacological strategies, while foundational in PD management, are inherently limited by their generalized systemic distribution, which often results in subtherapeutic concentrations at the site of neuronal injury and off-target effects elsewhere. Additionally, these approaches do not interfere with the underlying neurodegenerative processes, nor do they promote neuronal regeneration. Modern neuroscience has thus shifted toward precision medicine and disease-modifying therapies, aiming to not only alleviate symptoms but to influence disease trajectory [5-7].

Targeted therapy, particularly through the application of nanomedicine, offers significant promise by enabling the direct delivery of therapeutic agents to specific neural tissues. These systems are designed to bypass the restrictive nature of the blood-brain barrier (BBB)-a formidable obstacle composed of tight junctions and enzymatic barriers that limit CNS drug access [8]. Using molecular ligands, receptor-mediated pathways, or stimuli-sensitive triggers, nanocarriers can be engineered to selectively localize within affected brain regions and release their cargo in response to pathological microenvironments. In this emerging therapeutic landscape, naturally derived neuroprotective agents have garnered renewed interest due to their multifaceted actions and historical clinical use. *Ginkgo biloba and Gastrodia elata*, two extensively studied medicinal plants, are recognized for their potent antioxidant and anti-inflammatory capacities, as well as their ability to regulate neurotransmission, support mitochondrial health, and inhibit apoptotic pathways. *Ginkgo balboa's* terpene lactones and flavonoids are capable of modulating synaptic plasticity, improving cerebral blood flow, and neutralizing free radicals implicated in dopaminergic neuron injury [8-10].

In parallel, *Gastrodia elata's* gastrodin and related phenolic compounds demonstrate the ability to attenuate excitotoxicity, inhibit neuroinflammatory cascades, and enhance GABAergic neurotransmission, contributing to neurostabilization [9]. Importantly, both botanicals have shown

efficacy in ameliorating PD-like symptoms and protecting neuronal integrity in various experimental models, suggesting they may exert effects that complement or exceed conventional dopaminergic agents. Despite their therapeutic potential, the pharmacological application of these phytochemicals faces considerable challenges due to their low solubility, rapid metabolism, and inefficient penetration of the central nervous system. Nanoformulation technologies offer a transformative solution to these issues [8-10]. By encapsulating *Ginkgo and Gastrodia* constituents within biocompatible nanosystems-such as polymeric micelles, lipid-based NPs, or dendritic carriers-their stability, solubility, and transport across the BBB can be significantly enhanced [11].

These delivery platforms not only improve pharmacokinetics but also enable fine-tuned release kinetics and dual-drug loading strategies, paving the way for synergistic therapeutic outcomes. The development of these nano-herbal systems is informed by a growing body of *in vitro* and *in vivo* research, which demonstrates improved neuronal uptake, reduced oxidative stress, and preservation of dopaminergic terminals following targeted administration. The convergence of time-honored botanical wisdom with frontier nanotechnologies represents a paradigm shift in the treatment of neurodegenerative diseases. Rather than viewing traditional medicine and modern drug design as separate domains, their integration provides a fertile ground for innovation, particularly in conditions where current pharmacotherapy is palliative rather than curative [12-13]. Moving forward, the translation of nano-encapsulated *Ginkgo and Gastrodia* formulations from experimental models into clinical settings holds great potential to address unmet needs in PD care. This chapter explores this translational journey-from the phytochemical roots of traditional medicine to the nanoscale sophistication of targeted delivery-highlighting a future where ancient remedies are reimagined through the lens of cutting-edge biomedical science [14].

2. Current Status of Preclinical and Clinical Evidence

Preclinical investigations-comprising *in vivo*, *ex vivo,* and *in vitro* studies-form the backbone of translational research for evaluating the therapeutic potential of *Ginkgo biloba and Gastrodia elata* nanoformulations in PD. These studies are critical for assessing efficacy, mechanism of action, safety, and pharmacokinetics before advancing to clinical evaluation. Nanotechnology significantly enhances these botanicals biological activity by improving their solubility, bioavailability, stability, and ability to cross the blood-brain barrier (BBB) [14-15].

In vivo Studies

Animal models of PD, particularly those induced by neurotoxins such as 6-hydroxydopamine (6-OHDA), MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), and rotenone, are widely used to simulate the dopaminergic neuronal degeneration characteristic of PD. Several *in vivo* studies have demonstrated the enhanced efficacy of *Ginkgo biloba* and *Gastrodia elata* when delivered using nanotechnology-based systems [15].

Table 10.1 List of *in vivo* Studies of *Ginkgo biloba and Gastrodia elata* Nanoformulations in PD Models [14-16]

Study Component	Details
Animal Models Used	Neurotoxin-induced PD models: 6-OHDA, MPTP and Rotenone
Ginkgo biloba Nanoformulations	Carrier System: PLGA NPs Key Findings: Improved motor function, Increased striatal dopamine, Protection of TH-positive neurons in substantia nigra, Reduced MDA (oxidative stress marker) and Enhanced SOD and CAT (antioxidant enzymes)
Gastrodia elata Nanoformulations	Delivery Systems: Lipid NPss, polymeric carriers Key Findings: Anti-inflammatory and anti-apoptotic effects, Reduced microglial activation, Decreased TNF-α, IL-1β levels, Preservation of dopaminergic neurons and Intranasal gastrodin improved brain bioavailability and locomotor outcomes compared to oral delivery
Co-delivery (*Ginkgo* + *Gastrodia*)	Formulation: Dual-loaded nanoemulsion Key Findings: Synergistic neuroprotection, Improved motor behavior and mitochondrial function, Reduced α-synuclein accumulation and Lowered neuroinflammation
Non-motor Symptom Reversal	• Improvement in anxiety and cognitive impairment • Addressed often-overlooked symptoms of PD
Safety Profile	• Long-term use showed no significant hepatotoxicity or nephrotoxicity

***Ex vivo* Studies**

Ex vivo studies, often conducted on isolated tissues from treated animals, provide important insights into drug distribution, organ-level responses, and functional effects post-administration. These are particularly useful for evaluating the biodistribution, brain targeting efficiency, and tissue-specific antioxidant effects of herbal NPs [16-17].

Table 10.2: List of *ex vivo* Studies of *Ginkgo biloba and Gastrodia elata* Nanoformulations in PD [16-19]

Study Focus	Details & Findings
Brain Slice Assays	• Higher concentrations of ginkgolides and gastrodin observed in the striatum and substantia nigra in nano-treated PD rats • Indicates effective blood-brain barrier (BBB) penetration compared to conventional formulations
Organ-Specific Biodistribution	• Assessed using HPLC and LC-MS/MS techniques • Nanoformulations show preferential accumulation in the brain • Supports lower systemic toxicity
Mitochondrial Function Assays	• Conducted on isolated brain mitochondria • Nanoformulations preserved mitochondrial membrane potential • Increased ATP synthesis • Prevented cytochrome c release → Enhances neuronal survival
Ex vivo BBB Models	• Models constructed using endothelial cells and astrocytes from animal tissue • Chitosan- and polysorbate-80-coated NPs showed improved transendothelial permeability of ginkgolides and gastrodin • Confirms brain-targeting efficiency observed in *in vivo* studies

***In vitro* Studies**

In vitro models provide a controlled environment to dissect the cellular and molecular mechanisms underlying the neuroprotective effects of nanoformulated herbal compounds. Various neuronal and glial

cell lines are used, including SH-SY5Y (dopaminergic), PC12 (catecholaminergic), and BV2 (microglial) [20].

Table 10.3: List of *in vitro* studies in PD with details finding [18-21]

Study Focus	Details & Findings
Neuroprotection & Oxidative Stress	• *Ginkgo biloba* NPs reduce ROS in H_2O_2/MPP^+-challenged SH-SY5Y cells • Increase antioxidant enzymes, Preserve cell viability, reduce LDH leakage • Inhibit apoptotic markers (caspase-3, Bax)
Anti-inflammatory Activity	• Gastrodin-loaded NPs inhibit LPS-induced inflammation in BV2 cells • Downregulate NF-κB and MAPK • Suppress NO and cytokine release
Mitochondrial Protection	• JC-1 and TMRE assays show maintained mitochondrial membrane potential • Suggests energy metabolism preservation and reduced mitochondrial-mediated apoptosis
Cellular Uptake & Trafficking	• Fluorescent-tagged NPs show enhanced internalization • Surface modifications (PEGylation, ligand conjugation) further boost uptake into dopaminergic neurons
BBB Penetration (*in vitro*)	• Transwell co-culture models show higher permeability and lower efflux for nanoformulations • Supports enhanced brain targeting
Cytotoxicity & Advanced Models	• MTT and Trypan blue assays show non-toxicity at therapeutic doses • 3D cultures and microfluidic PD models simulate *in vivo* conditions more accurately

Preclinical studies encompassing *in vivo*, *ex vivo*, and *in vitro* models consistently highlight the enhanced efficacy and mechanistic depth of *Ginkgo biloba* and *Gastrodia elata* when delivered via nanoformulations in *PD*. These formulations demonstrate significant improvements in brain targeting, neuroprotection, antioxidant defense, and anti-inflammatory action while maintaining safety profiles across diverse models. *Ex vivo* tissue studies and advanced cell models further confirm their potential in overcoming the limitations of conventional herbal therapies. Collectively, these findings offer a robust scientific foundation for advancing herbal nanomedicines toward clinical application in PD and underscore the critical role of integrated preclinical research in driving translational success [21-23].

3. Pathophysiology of PD

An in-depth comprehension of the pathophysiology underlying PD bears significant clinical implications for both diagnostic and therapeutic strategies. The advancement of α-synuclein-centric biomarkers, encompassing seed amplification assays and imaging modalities, holds promise for facilitating earlier and more precise diagnostic outcomes. The identification of disparate PD subtypes (brain-first versus body-first) may further enable tailored therapeutic interventions [24]. The pathophysiological mechanisms of *PD* are characterized by the aggregation of α-synuclein, leading to the formation of Lewy bodies, a progressive decline in dopaminergic neurons within the substantia nigra, neuroinflammatory responses accompanied by microglial activation, mitochondrial dysfunction,

genetic predispositions, compromised protein clearance mechanisms, prion-like propagation, and the emergence of non-motor symptoms resulting from extensive α-synuclein pathology that impacts diverse brain regions and peripheral systems [23-25].

Molecular Mechanisms:

Aggregation of Alpha-Synuclein and Formation of Lewy Bodies: The misfolding and aggregation of proteins, particularly α-synuclein (α-syn), is integral to synaptic functionality and neurotransmitter release under physiological conditions. However, its aberrant misfolding and aggregation constitute the primary pathogenic mechanism in PD. The protein engages in a multifaceted aggregation pathway characterized by oligomerization and the development of insoluble fibrils, which form the distinctive Lewy bodies and Lewy neurites. This aggregation mechanism entails the transition of α-synuclein from its native conformation to pathological states. These misfolded variants disrupt essential cellular functions, including synaptic integrity, mitochondrial stability, and proteostasis, ultimately leading to neuronal apoptosis. The formation of α-synuclein oligomers is particularly detrimental, as these intermediary entities can provoke cellular dysfunction prior to the maturation of fibrillar structures [24-25].

Lewy Body Pathology: Lewy bodies serve as the pathological signature of PD, primarily comprising aggregated α-synuclein in conjunction with various other proteins. These intraneuronal aggregates are observed not solely in dopaminergic neurons but also across other neuronal populations within the central nervous system and peripheral nervous system. The accumulation of α-synuclein within Lewy bodies is correlated with the advancement of the disease and neuronal impairment.

Degeneration of Dopaminergic Neurons in the Substantia Nigra and Selective Vulnerability: The substantia nigra pars compacta (SNpc) exhibits marked susceptibility to α-synuclein pathology, with a progressive attrition of dopaminergic neurons representing a defining characteristic of PD. This selective vulnerability may be attributed to the heightened metabolic requirements of these neurons, along with their extensive axonal networks. Functional Alterations Preceding Neuronal Death: Pathophysiological alterations in dopaminergic neurons occur prior to their eventual demise, contributing to the initial phases of PD. The overexpression of α-synuclein diminishes the functional availability of D2 receptors, leading to dysregulation in firing patterns, dopamine release, and neuronal morphology. These functional disruptions may be partially ameliorated by D2 receptor agonists, yielding mechanistic insights pertinent to contemporary therapeutic strategies [25-27].



Figure 10.1: Schematic representation of pathogenic sequence in PD with details

Progressive Neurodegeneration:

The loss of dopaminergic neurons follows a progressive pattern, with studies showing that α-synuclein accumulation leads to structural and functional alterations in SNpc dopamine neurons, particularly at advanced stages of pathology. This neurodegeneration correlates with the development of motor symptoms and disease progression [28].

Neuroinflammation and Microglial Activation:

Glial Response to α-Synuclein α-Synuclein pathology extends beyond neurons to encompass glial cells, including microglia and astrocytes. Once α-synuclein is internalized by glial cells, they can act as neuroprotective scavengers limiting the spread of pathological protein. However, they can also become reactive, contributing to neuroinflammation and PD progression. Microglial Activation Patterns Microglial activation represents a key feature of PD pathogenesis, with activated microglia found in post-mortem PD brains. The complement and coagulation cascade pathways are enriched in PD mouse models, with complement component 3 (C3)-positive astrocytes increased in the ventral midbrain. C3 secreted from astrocytes can induce degeneration of dopaminergic neurons, highlighting the role of complement-mediated neuroinflammation [27-29].

Immune System Involvement Recent evidence indicates that adaptive immunity plays a significant role in PD pathogenesis. CD8+ T cells are enriched in the PD substantia nigra and show clonal expansion with T cell receptor sequences having homology to α-synuclein-reactive cells. These T cells are spatially correlated with CD44+ astrocytes, which increase in the PD brain and contribute to neuroinflammatory signatures. Mitochondrial Dysfunction and Oxidative Stress Mitochondrial Impairment α-Synuclein aggregation disrupts mitochondrial integrity, leading to impaired cellular energy production. Abnormal mitochondrial function is identified in both monogenic and sporadic PD,

representing a convergent pathway in disease pathogenesis. This dysfunction contributes to increased oxidative stress and cellular vulnerability [30].

Progressive Neurodegeneration:

The degeneration of dopaminergic neurons manifests in a progressive trajectory, as research indicates that the accumulation of α-synuclein precipitates both structural and functional modifications within SNpc dopamine neurons, particularly evident in the later stages of the disease. This neurodegenerative process is closely associated with the onset of motor symptoms and the advancement of the pathology [31].

Neuroinflammation and Microglial Activation:

Glial Response to α-Synuclein, the pathological effects of α-synuclein extend to glial cells, which include microglia and astrocytes. Upon the internalization of α-synuclein by these glial cells, they may function as neuroprotective agents that curtail the dissemination of the pathological protein. Conversely, they may also become activated, thereby exacerbating neuroinflammation and facilitating the progression of PD. Microglial Activation Patterns The activation of microglia constitutes a pivotal characteristic of PD pathogenesis, with evidence of activated microglia present in post-mortem brains of individuals with PD. The complement and coagulation cascade pathways exhibit significant enrichment in PD mouse models, with an increase in complement component 3 (C3)-positive astrocytes observed in the ventral midbrain. C3 released by astrocytes has the potential to induce degeneration of dopaminergic neurons, underscoring the significance of complement-mediated neuroinflammatory processes [32-33].

Immune System Involvement:

Recent findings suggest that adaptive immunity is critically involved in the pathogenesis of PD. CD8+ T cells are found in elevated numbers within the substantia nigra of PD patients, demonstrating clonal expansion alongside T cell receptor sequences that exhibit homology to α-synuclein-reactive cellular populations. These T cells are spatially associated with CD44+ astrocytes, which are increased in the PD-affected brain and contribute to the neuroinflammatory landscape [34]. Mitochondrial Dysfunction and Oxidative Stress Mitochondrial Impairment. The aggregation of α-synuclein disrupts mitochondrial function, resulting in compromised cellular energy production. Abnormalities in mitochondrial function have been identified in both familial and sporadic forms of PD, representing a unified pathological pathway in the disease process. Such dysfunction is implicated in the escalation of oxidative stress and cellular susceptibility. Oxidative Stress Mechanisms:

The buildup of misfolded α-synuclein incites oxidative stress via various mechanisms, including mitochondrial impairment and the disruption of cellular antioxidant systems. This oxidative injury

exacerbates protein misfolding and aggregation, thereby establishing a detrimental cycle of cellular dysfunction [34-35].

Dopamine Metabolism and Toxicity:

Dysregulation of dopamine metabolism plays a role in the degeneration of nigrostriatal neurons in PD. The dopamine metabolite DOPAL (3,4-dihydroxyphenylacetaldehyde) is found at elevated levels in PD patients and has the capacity to covalently modify α-synuclein, instigating oligomerization within dopaminergic neurons. The accumulation of DOPAL-induced α-synuclein undermines synaptic integrity and overwhelms the pathways responsible for protein quality control [36].

Risk Genes and Pathways:

Genomic investigations have pinpointed numerous genes that elevate the risk of PD, including GBA1, LRRK2, VPS35, PINK1, DJ-1, and Parkin. These genes converge on shared pathways involving endosomal, lysosomal, and mitochondrial dysfunction, thereby elucidating the underlying mechanisms of the disease.

4. Nanotechnology in Drug Delivery for PD

Nanotechnology offers a promising frontier for enhancing the therapeutic potential of traditional herbal extracts like *Ginkgo biloba* and *Gastrodia elata* in the treatment of PD. Nanoformulations such as liposomes, polymeric NPs, solid lipid NPs, and nanoemulsions are being explored to encapsulate the bioactive constituents of these botanicals. These nano-carriers not only protect phytochemicals like ginkgolides, bilobalide, and gastrodin from degradation but also improve solubility, stability, and BA parameters that are often limiting in conventional herbal preparations [37].

Several studies have demonstrated the neuroprotective effects of *Ginkgo biloba* through its antioxidant, anti-inflammatory, and anti-apoptotic mechanisms. When encapsulated into polymeric NPs, these effects are significantly enhanced, showing increased neuronal uptake and a reduction in dopaminergic neuron loss in PD models. Similarly, *Gastrodia elata*, rich in gastrodin and vanillyl alcohol, exhibits anticonvulsant and anti-inflammatory properties that have shown synergistic effects when delivered through nanocarriers. Advanced nanoformulations can be engineered to achieve site-specific delivery within the central nervous system (CNS). For instance, surface-modified NPss with ligands targeting the transferrin or insulin receptors have demonstrated promising brain-targeting capabilities.

Furthermore, combining both botanical extracts into a single nanoformulation holds potential for a dual-targeted therapy that could modulate multiple pathological pathways in PD, including oxidative stress, mitochondrial dysfunction, and neuroinflammation. One of the most critical challenges in CNS drug delivery, particularly for *PD*, is the selective permeability of the BBB. The BBB acts as a physiological gatekeeper, impeding the entry of most pharmacological agents into the brain parenchyma. To circumvent this, nanocarriers have been designed to exploit receptor-mediated transcytosis, adsorptive-

mediated endocytosis, and carrier-mediated transport. Recent advances in BBB-targeting involve the use of ligand-functionalized NPs [38-39]. These systems leverage specific ligands such as transferrin, lactoferrin, apolipoprotein E, and cell-penetrating peptides that bind to receptors on the BBB, enhancing translocation across endothelial cells. For herbal extracts like *Ginkgo biloba* and *Gastrodia elata*, these strategies ensure that their neuroactive components reach the desired site of action in therapeutic concentrations [40].

However, despite significant progress, several limitations remain. The variability in BBB permeability across individuals, disease progression, and NPs composition often leads to inconsistent results in vivo. Additionally, the potential for immune recognition and clearance by the reticuloendothelial system (RES) remains a challenge. Emerging technologies such as biomimetic NPs-engineered using cell membrane coatings—and exosome-based delivery systems offer a promising alternative by providing improved biocompatibility and immune evasion. The dynamic nature of the BBB in PD, which can vary due to inflammation and neurodegeneration, also provides an opportunity for passive targeting through enhanced permeability [41]. NPs can be tuned for size, surface charge, and hydrophobicity to exploit these transient windows of opportunity. Still, precision in targeting must be balanced with safety and long-term biostability to minimize off-target effects and systemic toxicity. Controlled release formulations are essential in maintaining therapeutic drug concentrations over extended periods, thereby improving treatment adherence and minimizing dose-related side effects. In the context of *PD*, where chronic treatment is required, and motor fluctuations are common, nanocarrier systems that allow for sustained release of therapeutic agents present a significant clinical advantage [42-43].

Polymeric NPs, especially those based on PLGA (poly (lactic-co-glycolic acid)) and chitosan, have been extensively researched for their ability to provide controlled drug release. These systems can be designed to respond to physiological stimuli such as pH, temperature, or enzyme activity, ensuring drug release only at the target site. In the case of *Ginkgo biloba* and *Gastrodia elata*, encapsulating their active phytoconstituents into such biodegradable polymers can prevent premature degradation and allow for slow, consistent diffusion into neural tissues. Hydrogels and nanogels represent another class of delivery vehicles capable of loading and releasing bioactives in a time-controlled manner [44]. These systems are particularly valuable for intranasal or intracerebral routes, offering the advantage of bypassing first-pass metabolism and directly targeting the CNS. Moreover, layered double hydroxide (LDH) nanocarriers and mesoporous silica NPs have shown potential in modulating release kinetics via surface modifications. Microneedle arrays and implantable nanosystems, though still in the preclinical stage, offer a vision for non-invasive, long-acting delivery platforms [44-45].

These technologies could eventually revolutionize PD therapy by reducing the frequency of administration while maintaining consistent therapeutic efficacy. For dual-extract systems containing both *Ginkgo* and *Gastrodia*, designing formulations with staggered or sequential release profiles could optimize the timing of therapeutic action and enhance synergistic effects. While nanotechnology opens

new doors for PD treatment, its clinical translation is contingent upon thorough evaluation of biocompatibility and safety. NPs interact with biological systems at a molecular level, and unintended effects such as cytotoxicity, immunogenicity, or accumulation in off-target tissues must be carefully assessed. Herbal-based NPs, though perceived as natural and safer, still require rigorous toxicological studies to establish their safety profiles. Surface properties of NPs-such as charge, hydrophobicity, and functional groups-can significantly influence their interaction with cells and proteins. Cationic NPs, for instance, may offer higher cellular uptake but also pose a risk for membrane disruption and inflammation. The selection of materials, whether synthetic or natural polymers, should prioritize biocompatibility, biodegradability, and non-immunogenicity. *In vivo* studies involving animal models of PD have reported minimal systemic toxicity with herbal nanoformulations when appropriate dosage and particle size ranges are maintained [44-46]. Still, long-term biodistribution, clearance pathways, and accumulation in organs such as the liver, spleen, and kidneys need to be thoroughly mapped. Analytical tools such as fluorescence imaging, mass spectrometry, and electron microscopy can provide insights into NPs behavior post-administration.

Moreover, regulatory requirements mandate a multi-tiered evaluation encompassing acute, sub-chronic, and chronic toxicity studies, genotoxicity, and reproductive toxicity. Establishing standardized protocols for evaluating herbal nanomedicines remains a challenge due to the inherent complexity and variability of plant extracts. The integration of quality-by-design (QbD) principles in NPs fabrication offers a systematic approach to ensuring safety and reproducibility. Factors such as particle size distribution, zeta potential, and encapsulation efficiency should be closely monitored to achieve consistent performance. Collaboration between pharmacologists, toxicologists, and material scientists is essential to bridge the gap between preclinical promise and clinical application [45-48].

The future of PD management may well be shaped by nanotechnology-enabled delivery systems that can harness the full therapeutic potential of traditional herbs like *Ginkgo biloba* and *Gastrodia elata*. From engineering advanced nanoformulations and optimizing BBB penetration to ensuring sustained release and biocompatibility, each component plays a vital role in translating bench-side innovations into bedside therapies. Continued interdisciplinary research and regulatory harmonization will be pivotal in realizing the clinical promise of these novel therapeutics [49].

5. Biomarkers and Personalized Medicine

Biomarkers are objective indicators of physiological or pathological processes and can be used to assess disease progression, predict treatment responses, or monitor adverse effects. In PD, where early diagnosis and individualized therapy remain clinical challenges, the identification of reliable biomarkers is a top research priority-particularly when introducing novel treatments like herbal nanomedicines. Biomarkers for **efficacy** often include biochemical and imaging-based measures of dopaminergic function [50]. PET and SPECT imaging using tracers such as DOPA or DAT ligands can

quantify nigrostriatal dopaminergic neuron integrity, providing a functional readout of neuroprotective effects. Studies investigating nanoformulations of *Ginkgo* and *Gastrodia* can utilize these imaging markers to validate therapeutic action, particularly in slowing neurodegeneration.

Fluid biomarkers, such as α-synuclein, DJ-1, and neurofilament light chain (NfL), measured in cerebrospinal fluid (CSF) or blood, serve as non-invasive indicators of disease state and therapeutic response. Gastrodin, for instance, has been shown in preclinical studies to reduce α-synuclein aggregation-this can be validated in clinical settings by monitoring serum or CSF α-synuclein levels in patients treated with nano-gastrodin. In addition to efficacy, safety biomarkers are equally critical. As nanomedicines alter the pharmacokinetic profile of bioactive compounds, there is a need to monitor liver and kidney function markers, oxidative stress indicators, and inflammatory cytokines to ensure systemic safety [51-52]. Glutathione (GSH) levels, C-reactive protein (CRP), and IL-6 are often evaluated as systemic toxicity biomarkers, and their fluctuations can guide dosage adjustments. Emerging approaches also involve pharmacodynamic biomarkers, which reflect drug–target engagement [53]. For example, a decrease in pro-inflammatory cytokines or microglial activation markers in blood or CSF post-treatment can indicate the anti-inflammatory effectiveness of *Gastrodia elata* NPs. Furthermore, omic-based biomarkers-including transcriptomics, metabolomics, and proteomics-are being investigated to provide a more comprehensive view of disease modulation. These high-throughput techniques can help identify changes in gene expression, protein profiles, or metabolic pathways in response to herbal nanotherapies, laying the foundation for predictive biomarker discovery [54-55].

5.2 Genetic Variability in *PD* and Response to Botanicals

Genetic heterogeneity significantly influences both the pathophysiology of PD and patient responses to pharmacological and herbal therapies. Mutations in genes such as LRRK2, PARK7, PINK1**,** SNCA, and GBA are associated with different PD phenotypes, disease progression rates, and treatment sensitivities. Personalized medicine approaches must account for these genetic variants to tailor interventions more effectively. For instance, patients carrying GBA mutations are more prone to cognitive decline and may require therapeutic agents with neuroprotective and anti-inflammatory properties. Since both *Ginkgo biloba* and *Gastrodia elata* exhibit antioxidative and neurotrophic effects, understanding their specific activity profiles in GBA-related PD could enhance treatment personalization [56]. Likewise, the mitochondrial dysfunction observed in PINK1 and PARKIN mutations suggests that botanical extracts promoting mitochondrial health-such as gastrodin-may be more effective in these subtypes. Genetic polymorphisms can also affect drug metabolism and response. Cytochrome P450 (CYP) enzymes play a major role in metabolizing botanical compounds, and genetic differences in these enzymes can lead to inter-individual variability in plasma levels of ginkgolides or gastrodin. For example, CYP2C19 polymorphisms could alter the biotransformation of *Ginkgo* components, affecting both efficacy and toxicity [56-57].

Moreover, epigenetic regulation, including DNA methylation and histone modifications, influences how individuals respond to phytochemicals. Emerging studies show that compounds from *Ginkgo biloba* can exert epigenetic effects, such as modifying the expression of antioxidant genes. Understanding patient-specific epigenetic patterns may help predict responsiveness to these herbal therapies. In the nanomedicine, genetic factors may also impact NPs uptake and distribution. Variants in genes encoding for receptors involved in NPs transcytosis (e.g., transferrin or insulin receptors) could influence how efficiently these carriers cross the BBB and reach target neuronal tissues. Personalized dosing or formulation adjustments may be necessary to accommodate such variations. Integrating genetic screening into PD management could thus enable a more tailored approach to botanical therapy [58]. Companion diagnostics and genetic profiling could be used not only to predict responsiveness but also to avoid adverse effects, ensuring both efficacy and safety in a genetically diverse patient population.

5.3 Role of Artificial Intelligence in Patient Stratification

Artificial intelligence (AI) has emerged as a powerful tool for managing complex, multi-dimensional datasets, making it particularly valuable for personalized medicine in PD. AI algorithms-especially machine learning (ML) and deep learning (DL) models-can integrate clinical, genetic, biochemical, and imaging data to stratify patients into biologically relevant subgroups, predict disease trajectories, and recommend optimal treatments.

In the herbal nanomedicines, AI can assist in biomarker discovery, identifying which combinations of biological indicators most accurately predict response to *Ginkgo* or *Gastrodia* therapy. For example, unsupervised clustering techniques like k-means or hierarchical clustering can group patients based on their biomarker profiles (e.g., inflammation markers, neurodegeneration signatures), enabling targeted intervention strategies.AI models can also analyze genetic data to predict responders and non-responders to botanical treatments. By training models on genetic variants, epigenetic patterns, and prior treatment outcomes, AI can forecast likely therapeutic benefit or toxicity risk for individual patients, guiding selection of the most suitable herbal formulations and doses. Furthermore, real-world data integration-from wearable devices, electronic health records (EHRs), and digital biomarkers-allows AI to continuously monitor patient responses to treatment. This facilitates adaptive treatment planning, where dosages or formulations can be adjusted dynamically based on patient-specific feedback [59]. For instance, wearable sensor data capturing tremor intensity, gait speed, or sleep patterns can be analyzed in real time to assess therapeutic efficacy and suggest modifications. Another exciting application is in nanomedicine formulation optimization. AI algorithms can be employed to design NPs carriers tailored to patient-specific parameters, such as age-related BBB permeability or metabolism rate. This precision-guided nanocarrier development ensures maximum therapeutic targeting while minimizing off-target effects. As AI technologies mature, their integration with multi-omic data, clinical phenotyping, and nanomedicine will be central to the next generation of personalized PD therapies [60].

Finally, natural language processing (NLP**)** and AI-driven literature mining can accelerate the identification of novel phytoconstituents, biomarkers, and gene interactions relevant to PD and herbal treatment. These tools can synthesize vast biomedical data to inform clinical decision-making, regulatory approval, and research prioritization.

6. Future Research Directions

As the field of nanotechnology-based therapeutics for PD continues to evolve, future research directions are increasingly focusing on overcoming current limitations in efficacy, targeting, and long-term safety, while also embracing synergies with emerging biomedical technologies. One of the most promising advancements lies in the development of next-generation nano-carriers, such as exosomes, dendrimers, and stimuli-responsive delivery platforms. Unlike traditional NPs, exosomes-endogenously derived extracellular vesicles-offer a highly biocompatible and inherently targeted delivery system capable of crossing the blood-brain barrier (BBB) with minimal immune recognition [61]. Their natural origin and ability to carry complex biological cargo such as proteins, RNAs, and small molecules make them ideal candidates for encapsulating and delivering phytoconstituents from herbs like *Ginkgo biloba* and *Gastrodia elata*. Moreover, exosomes can be engineered to express surface ligands or antibodies that improve their affinity for dopaminergic neurons, enabling a precision-targeted approach for PD therapy.

Similarly, dendrimers, with their highly branched, monodisperse, and customizable architecture, allow for precise control over drug loading, release kinetics, and surface functionality. These carriers can be functionalized with moieties that enhance cellular uptake, reduce systemic clearance, and minimize off-target toxicity, thereby improving the delivery efficiency of herbal bioactives. Recent research has also explored stimuli-responsive carriers, which release their payload in response to physiological triggers such as pH, redox gradients, or enzymatic activity prevalent in inflamed or diseased brain tissues. These "smart" systems could enable site-specific delivery of ginkgolides or gastrodin, further minimizing systemic exposure and adverse effects. As carrier technology advances, the potential to integrate multi-functional systems-such as theranostic NPs combining imaging and therapeutic capabilities-will provide real-time tracking and personalized dosing adjustments based on disease progression [61-62].

In parallel, the integration of CRISPR-Cas gene editing technologies with botanical therapeutics opens novel avenues for synergistic treatment strategies. *PD*, with its well-documented genetic contributors (e.g., SNCA, LRRK2, PARK7, PINK1, and GBA), offers a compelling model for gene-targeted therapies. CRISPR-based tools could be used to correct disease-causing mutations or silence deleterious gene expressions, while herbal nanoformulations can complement these effects by modulating cellular stress, mitochondrial dysfunction, and inflammation [64]. For instance, gastrodin-loaded NPs could be administered alongside CRISPR-Cas systems designed to knock down alpha-synuclein overexpression, thereby tackling both the genetic and biochemical hallmarks of PD. The anti-inflammatory and neurotrophic effects of *Ginkgo* compounds could further stabilize the cellular environment, improving

the success rate of gene editing in diseased neurons. Moreover, nano-delivery systems offer an efficient platform to co-deliver gene-editing payloads (Cas9 RNP complexes) and herbal actives in a synchronized and tissue-specific manner. This combinatorial approach may significantly enhance therapeutic outcomes, reduce the dosage requirements of either modality, and mitigate off-target gene editing risks. However, this emerging synergy demands a more comprehensive understanding of NPs-genome interactions, immune compatibility, and regulatory pathways. The design of dual-action nano-systems capable of delivering both natural compounds and CRISPR elements in a temporally controlled sequence represents a promising but complex frontier in PD therapeutics [63-65].

Another critical area that warrants deeper exploration is the long-term toxicology and biodistribution of nano-herbal formulations. While short-term animal studies have provided preliminary evidence of safety and efficacy, chronic exposure data remain sparse. The unique physicochemical properties of NPs-including size, shape, surface charge, and composition-can influence their accumulation, metabolism, and clearance from biological systems. Herbal nanoformulations, though generally perceived as safer due to their natural origins, must still undergo rigorous long-term toxicological evaluations to ensure they do not elicit immunogenic responses, organ damage, or genotoxic effects upon repeated administration [66]. Extended biodistribution studies using advanced imaging techniques such as positron emission tomography (PET), magnetic resonance imaging (MRI), and fluorescence-based tracking can offer real-time insights into NPs localization in organs such as the brain, liver, spleen, and kidneys. Special attention should be paid to evaluating NPs degradation products, potential interactions with endogenous macromolecules, and their influence on hepatic or renal pathways [65-66].

Additionally, aging-related changes in pharmacokinetics-especially relevant to elderly PD populations-must be systematically studied to understand how altered BBB integrity, immune function, and organ performance affect NPs behavior over time. Establishing standardized testing protocols, including chronic toxicity, reproductive toxicity, and immunotoxicity assessments, will be essential for regulatory approval and clinical translation [67]. Furthermore, integrating *in-silico* models and computational toxicology can streamline this process by predicting long-term risks based on NPs characteristics and biological interactions, helping prioritize the most promising candidates for extended *in vivo* validation [66-67].

Equally important is the need to establish robust real-world evidence (RWE) and post-market surveillance systems once herbal nanomedicines enter clinical use. While randomized controlled trials (RCTs) remain the gold standard for initial efficacy evaluation, they often operate under controlled conditions that may not capture the full spectrum of real-world variability in patient behavior, co-morbidities, and long-term adherence. RWE, derived from electronic health records (EHRs), patient registries, wearable devices, and patient-reported outcomes, can provide a more holistic view of how these therapies perform across diverse populations [67]. This is particularly valuable for complex

treatments like *Ginkgo* and *Gastrodia*-based nanoformulations, where individual responses may be influenced by genetic background, environmental exposures, and co-administered medications. Establishing large-scale, prospective observational cohorts will enable continuous data collection on treatment effectiveness, adverse events, and quality-of-life metrics over extended periods. Real-world insights can inform adaptive dosing strategies, identify rare or delayed adverse effects, and guide label updates or usage recommendations. Post-market pharmacovigilance systems should be designed to capture nano-specific safety data, such as NPs-related hypersensitivity reactions, bioaccumulation risks, or unforeseen interactions with existing medications [68]. Furthermore, incorporating artificial intelligence and machine learning algorithms into post-marketing data analysis can enhance the detection of subtle patterns and early safety signals, facilitating timely regulatory interventions and improving patient outcomes. Engaging patients, clinicians, and pharmacists in post-market feedback loops-through digital platforms or mobile health applications-can also foster better monitoring, adherence, and trust in nano-herbal therapeutics [69].

In conclusion, the future of herbal nanomedicine in PD lies at the intersection of advanced nanocarrier innovation, molecular precision via gene editing, robust long-term safety validation, and real-world application monitoring. Each of these domains-whether it's developing biologically intelligent nano-vehicles, leveraging CRISPR for personalized genomic interventions, or designing predictive toxicological models-contributes to a more holistic and individualized treatment paradigm [66-68]. Cross-disciplinary collaboration between nanotechnologists, neuroscientists, geneticists, data scientists, and clinicians will be essential to navigate these frontiers. As regulatory frameworks evolve and patient-centered innovation becomes the norm, these future research directions will not only enhance therapeutic efficacy but also ensure safety, scalability, and accessibility of botanical nanoformulations, ultimately bridging the gap between ancient phytomedicine and modern neurotechnology in the ongoing battle against PD [68-70].

Conclusion

Ginkgo biloba and Gastrodia elata exhibit potential in the treatment of PD owing to their antioxidant, anti-inflammatory, and neuroprotective characteristics. The application of nanotechnology (including liposomes, NPs, and nanoemulsions) enhances their solubility, bioavailability, and delivery to the brain, with preclinical studies indicating their effectiveness. Nonetheless, there are challenges such as variability in herbal extracts, a lack of standardization, regulatory obstacles, insufficient long-term safety data, and a scarcity of large-scale clinical trials. Future research should focus on patient-centered, multi-targeted therapies that combine nanomedicine with genetics, artificial intelligence, digital health, and microbiome strategies. This integration of traditional herbal medicine with contemporary technology has the potential to slow the progression of PD and improve patient outcomes. The ethical and societal aspects of this translational shift will be equally significant. Ensuring fair access, tackling long-term safety issues, and maintaining the cultural significance of traditional medicine are essential for developing sustainable innovation frameworks. In the future envisioned, the integration of ancient botanicals, cutting-edge nanotechnology, and precision healthcare has the potential to advance PD treatment from merely managing symptoms to implementing disease-modifying strategies. In this future, the phrase "bench to bedside" will represent not only the application of scientific breakthroughs in clinical settings but also the development of comprehensive, patient-specific therapies that can significantly change the course of PD and enhance the quality of life globally.

Acknowledgement: Authors would like to thank Editors, Deep Science Publishers and Department of Pharmacy, Jagannath University to provide this opportunity.

Author Contribution: All authors have equal contributions in completion of this book chapter.

Fundings: No funding.

Conflict of Interest: There is no conflict of interest.

References

1. Bloem BR, Okun MS, Klein C. Parkinson's disease. The Lancet. 2021 Jun 12;397(10291):2284-303.
2. Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson's disease. The Lancet Neurology. 2021 May 1;20(5):385-97.
3. Ben-Shlomo Y, Darweesh S, Llibre-Guerra J, Marras C, San Luciano M, Tanner C. The epidemiology of Parkinson's disease. The Lancet. 2024 Jan 20;403(10423):283-92.
4. Morris HR, Spillantini MG, Sue CM, Williams-Gray CH. The pathogenesis of Parkinson's disease. The Lancet. 2024 Jan 20;403(10423):293-304.
5. Weintraub D, Aarsland D, Chaudhuri KR, Dobkin RD, Leentjens AF, Rodriguez-Violante M, Schrag A. The neuropsychiatry of Parkinson's disease: advances and challenges. The Lancet Neurology. 2022 Jan 1;21(1):89-102.
6. Fanning S, Selkoe D, Dettmer U. PD: proteinopathy or lipidopathy?. NPJ Parkinson's disease. 2020 Jan 3;6(1):3.
7. Chia SJ, Tan EK, Chao YX. Historical perspective: models of PD. International journal of molecular sciences. 2020 Apr 2;21(7):2464.
8. Lee TK, Yankee EL. A review on PD treatment. Neuroimmunology and Neuroinflammation. 2021 Dec 21;8:N-A.
9. De Miranda BR, Goldman SM, Miller GW, Greenamyre JT, Dorsey ER. Preventing PD: an environmental agenda. Journal of PD. 2022 Jan 21;12(1):45-68.
10. Marino BL, de Souza LR, Sousa KP, Ferreira JV, Padilha EC, da Silva CH, Taft CA, Hage-Melim LI. PD: a review from pathophysiology to treatment. Mini reviews in medicinal chemistry. 2020 Jun 1;20(9):754-67.
11. Vijiaratnam N, Simuni T, Bandmann O, Morris HR, Foltynie T. Progress towards therapies for disease modification in Parkinson's disease. The Lancet Neurology. 2021 Jul 1;20(7):559-72.
12. Höglinger GU, Adler CH, Berg D, Klein C, Outeiro TF, Poewe W, Postuma R, Stoessl AJ, Lang AE. A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria. The Lancet Neurology. 2024 Feb 1;23(2):191-204.
13. Cherian A, Divya KP. Genetics of Parkinson's disease. Acta Neurologica Belgica. 2020 Aug 19:1-9.
14. Stoker TB, Barker RA. Recent developments in the treatment of Parkinson's Disease. F1000Research. 2020 Jul 31;9:F1000-aculty.
15. Hasan I, Roy S, Guo B, Chang C. Parkinson's disease: current status, diagnosis, and treatment using nanomedicines. Advanced Therapeutics. 2023 Sep;6(9):2300058.
16. Giuliano C, Cerri S, Blandini F. Potential therapeutic effects of polyphenols in PD: in vivo: and: in vitro: pre-clinical studies. Neural regeneration research. 2021 Feb 1;16(2):234-41.
17. Dos Santos MG, Schimith LE, André-Miral C, Muccillo-Baisch AL, Arbo BD, Hort MA. Neuroprotective effects of resveratrol in *in vivo* and *in vitro* experimental models of PD: A systematic review. Neurotoxicity Research. 2022 Feb;40(1):319-45.
18. El Elhaj A, Onger ME. Exploring Neurodegenerative Diseases: Bridging the Gap between *in vitro* and *in vivo* Models. Current Pharmaceutical Design. 2025.
19. Ke M, Chong CM, Zhu Q, Zhang K, Cai CZ, Lu JH, Qin D, Su H. Comprehensive perspectives on experimental models for PD. Aging and disease. 2021 Feb 1;12(1):223.
20. Sharma S, Rabbani SA, Agarwal T, Baboota S, Pottoo FH, Kadian R. Nanotechnology driven approaches for the management of PD: current status and future perspectives. Current drug metabolism. 2021 Apr 1;22(4):287-98.
21. Nakmode DD, Day CM, Song Y, Garg S. The management of PD: an overview of the current advancements in drug delivery systems. Pharmaceutics. 2023 May 15;15(5):1503.
22. Antonosante A, Castelli V, Sette M, Alfonsetti M, Catanesi M, Benedetti E, Ardini M, Cimini A, d'Angelo M. Neuroprotective effects of the PPARβ/δ antagonist GSK0660 in *in vitro* and *in vivo* PD models. Biological Research. 2023;56.

23. Thome AD, Atassi F, Wang J, Faridar A, Zhao W, Thonhoff JR, Beers DR, Lai EC, Appel SH. Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in PD. npj Parkinson's Disease. 2021 May 13;7(1):41.

24. Zhou ZD, Yi LX, Wang DQ, Lim TM, Tan EK. Role of dopamine in the pathophysiology of PD. Translational neurodegeneration. 2023 Sep 18;12(1):44.

25. Dirkx MF, Bologna M. The pathophysiology of Parkinson's disease tremor. Journal of the Neurological Sciences. 2022 Apr 15;435:120196.

26. Marino BL, de Souza LR, Sousa KP, Ferreira JV, Padilha EC, da Silva CH, Taft CA, Hage-Melim LI. PD: a review from pathophysiology to treatment. Mini reviews in medicinal chemistry. 2020 Jun 1;20(9):754-67.

27. Pan L, Meng L, He M, Zhang Z. Tau in the pathophysiology of PD. Journal of Molecular Neuroscience. 2021 Nov;71(11):2179-91.

28. Vázquez-Vélez GE, Zoghbi HY. Parkinson's disease genetics and pathophysiology. Annual review of neuroscience. 2021 Jul 8;44(1):87-108.

29. Zaman V, Shields DC, Shams R, Drasites KP, Matzelle D, Haque A, Banik NL. Cellular and molecular pathophysiology in the progression of PD. Metabolic brain disease. 2021 Jun;36(5):815-27.

30. Bloem BR, Okun MS, Klein C. Parkinson's disease. The Lancet. 2021 Jun 12;397(10291):2284-303.

31. Kouli A, Camacho M, Allinson K, Williams-Gray CH. Neuroinflammation and protein pathology in PD dementia. Acta neuropathologica communications. 2020 Dec 3;8(1):211.

32. Morris HR, Spillantini MG, Sue CM, Williams-Gray CH. The pathogenesis of Parkinson's disease. The Lancet. 2024 Jan 20;403(10423):293-304.

33. Simon DK, Tanner CM, Brundin P. Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clinics in geriatric medicine. 2020 Feb 1;36(1):1-2.

34. Aryal S, Skinner T, Bridges B, Weber JT. The pathology of PD and potential benefit of dietary polyphenols. Molecules. 2020 Sep 24;25(19):4382.

35. Heilman PL, Wang EW, Lewis MM, Krzyzanowski S, Capan CD, Burmeister AR, Du G, Escobar Galvis ML, Brundin P, Huang X, Brundin L. Tryptophan metabolites are associated with symptoms and nigral pathology in Parkinson's disease. Movement Disorders. 2020 Nov;35(11):2028-37.

36. Trinh D, Israwi AR, Arathoon LR, Gleave JA, Nash JE. The multi-faceted role of mitochondria in the pathology of PD. Journal of Neurochemistry. 2021 Mar;156(6):715-52.

37. Sharma S, Rabbani SA, Agarwal T, Baboota S, Pottoo FH, Kadian R. Nanotechnology driven approaches for the management of PD: current status and future perspectives. Current drug metabolism. 2021 Apr 1;22(4):287-98.

38. Baskin J, Jeon JE, Lewis SJ. Nanoparticles for drug delivery in PD. Journal of Neurology. 2021 May;268(5):1981-94.

39. Majumdar M, Badwaik H. Trends on novel targets and nanotechnology-based drug delivery system in the treatment of Parkinson's disease: recent advancement in drug development. Current Drug Targets. 2024 Dec;25(15):987-1011.

40. Hernández-Parra H, Cortés H, Avalos-Fuentes JA, Del Prado-Audelo M, Florán B, Leyva-Gómez G, Sharifi-Rad J, Cho WC. Repositioning of drugs for PD and pharmaceutical nanotechnology tools for their optimization. Journal of nanobiotechnology. 2022 Sep 15;20(1):413.

41. Pawar A, Patil A. Nanotechnology-Based Approaches for PD: Progress in Drug Delivery and Regenerative Medicine. Journal of Drug Delivery and Biotherapeutics. 2024 Oct 25;1(02):48-57.

42. Padilla-Godínez FJ, Ruiz-Ortega LI, Guerra-Crespo M. Nanomedicine in the face of PD: from drug delivery systems to nanozymes. Cells. 2022 Oct 31;11(21):3445.

43. Mittal KR, Pharasi N, Sarna B, Singh M, Rachana, Haider S, Singh SK, Dua K, Jha SK, Dey A, Ojha S. Nanotechnology-based drug delivery for the treatment of CNS disorders. Translational Neuroscience. 2022 Dec 31;13(1):527-46.

44. Ghazy E, Rahdar A, Barani M, Kyzas GZ. Nanomaterials for Parkinson disease: Recent progress. Journal of Molecular Structure. 2021 May 5;1231:129698.

45. Naqvi S, Panghal A, Flora SJ. Nanotechnology: a promising approach for delivery of neuroprotective drugs. Frontiers in neuroscience. 2020 Jun 9;14:494.

46. González LF, Bevilacqua LE, Naves R. Nanotechnology-based drug delivery strategies to repair the mitochondrial function in neuroinflammatory and neurodegenerative diseases. Pharmaceutics. 2021 Dec 1;13(12):2055.

47. Li A, Tyson J, Patel S, Patel M, Katakam S, Mao X, He W. Emerging nanotechnology for treatment of Alzheimer's and PD. Frontiers in Bioengineering and Biotechnology. 2021 May 25;9:672594.

48. Kiran P, Debnath SK, Neekhra S, Pawar V, Khan A, Dias F, Pallod S, Srivastava R. Designing nanoformulation for the nose-to-brain delivery in Parkinson's disease: Advancements and barrier. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2022 Jan;14(1):e1768.

49. Xiong S, Luo J, Wang Q, Li Z, Li J, Liu Q, Gao L, Fang S, Li Y, Pan H, Wang H. Targeted graphene oxide for drug delivery as a therapeutic nanoplatform against Parkinson's disease. Biomaterials Science. 2021;9(5):1705-15.

50. Khanna A, Jones G. Toward personalized medicine approaches for Parkinson disease using digital technologies. JMIR Formative Research. 2023 Sep 27;7(1):e47486.

51. Straccia G, Colucci F, Eleopra R, Cilia R. Precision medicine in PD: from genetic risk signals to personalized therapy. Brain Sciences. 2022 Sep 28;12(10):1308.

52. Trifonova OP, Maslov DL, Balashova EE, Urazgildeeva GR, Abaimov DA, Fedotova EY, Poleschuk VV, Illarioshkin SN, Lokhov PG. PD: available clinical and promising omics tests for diagnostics, disease risk assessment, and pharmacotherapy personalization. Diagnostics. 2020 May 25;10(5):339.

53. Dehestani M, Liu H, Gasser T. Polygenic risk scores contribute to personalized medicine of PD. Journal of personalized medicine. 2021 Oct 15;11(10):1030.

54. Schneider SA, Alcalay RN. Precision medicine in PD: emerging treatments for genetic PD. Journal of neurology. 2020 Mar;267(3):860-9.

55. Tanaka M. PD: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation. Cells. 2025 Jul 28;14(15):1161.

56. Fröhlich H, Bontridder N, Petrovska-Delacréta D, Glaab E, Kluge F, Yacoubi ME, Marín Valero M, Corvol JC, Eskofier B, Van Gyseghem JM, Lehericy S. Leveraging the potential of digital technology for better individualized treatment of Parkinson's disease. Frontiers in neurology. 2022 Feb 28;13:788427.

57. Domínguez-Fernández C, Egiguren-Ortiz J, Razquin J, Gómez-Galán M, De las Heras-García L, Paredes-Rodríguez E, Astigarraga E, Miguélez C, Barreda-Gómez G. Review of technological challenges in personalised medicine and early diagnosis of neurodegenerative disorders. International Journal of Molecular Sciences. 2023 Feb 7;24(4):3321.

58. Lukiw WJ, Vergallo A, Lista S, Hampel H, Zhao Y. Biomarkers for AD (AD) and the application of precision medicine. Journal of personalized medicine. 2020 Sep 21;10(3):138.

59. Pandey S, Jirásko M, Lochman J, Chvátal A, Chottova Dvorakova M, Kučera R. iPSCs in neurodegenerative disorders: A unique platform for clinical research and personalized medicine. Journal of Personalized Medicine. 2022 Sep 10;12(9):1485.

60. Marras C, Fereshtehnejad SM, Berg D, Bohnen NI, Dujardin K, Erro R, Espay AJ, Halliday G, Van Hilten JJ, Hu MT, Jeon B. Transitioning from subtyping to precision medicine in Parkinson's disease: a purpose-driven approach. Movement Disorders. 2024 Mar;39(3):462-71.

61. Obeso JA, Monje MH, Matarazzo M. Major advances in Parkinson's disease over the past two decades and future research directions. The Lancet Neurology. 2022 Dec 1;21(12):1076-9.

62. Park S. The Past, Present, and Future of Parkinson's Disease Treatment. Open Science Journal. 2020 Nov 18;5(4).

63. Gouda NA, Elkamhawy A, Cho J. Emerging therapeutic strategies for PD and future prospects: A 2021 update. Biomedicines. 2022 Feb 3;10(2):371.

64. Elsworth JD. PD treatment: Past, present, and future. Journal of neural transmission. 2020 May;127(5):785-91.

65. Olanow CW, Calabresi P, Obeso JA. Continuous dopaminergic stimulation as a treatment for Parkinson's disease: current status and future opportunities. Movement Disorders. 2020 Oct;35(10):1731-44.

66. Castonguay AM, Gravel C, Lévesque M. Treating PD with antibodies: Previous studies and future directions. Journal of PD. 2021 Feb 2;11(1):71-92.

67. Prasuhn J, Davis RL, Kumar KR. Targeting mitochondrial impairment in Parkinson's disease: challenges and opportunities. Frontiers in cell and developmental biology. 2021 Jan 5;8:615461.

68. Schumacher-Schuh AF, Bieger A, Okunoye O, Mok KY, Lim SY, Bardien S, Ahmad-Annuar A, Santos-Lobato BL, Strelow MZ, Salama M, Rao SC. Underrepresented populations in Parkinson's genetics research: current landscape and future directions. Movement Disorders. 2022 Aug;37(8):1593-604.

69. Krauss JK, Lipsman N, Aziz T, Boutet A, Brown P, Chang JW, Davidson B, Grill WM, Hariz MI, Horn A, Schulder M. Technology of deep brain stimulation: current status and future directions. Nature Reviews Neurology. 2021 Feb;17(2):75-87.

70. Cassotta M, Geerts H, Harbom L, Outeiro TF, Pediaditakis I, Reiner O, Schildknecht S, Schwamborn JC, Bailey J, Herrmann K, Hogberg HT. The future of PD research: A new paradigm of human specific investigation is necessary… and possible. ALTEX. 2022;2022(39/4):694-709.